Stomach Diseases  >>  epirubicin  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
epirubicin / Generic mfg.
RILOMET-1, NCT01697072 / 2011-004923-11: First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Terminated
3
609
US, Canada, Europe, RoW
Rilotumumab, AMG102, Placebo, sterile protein-free solution, Epirubicin, Ellence, Pharmorubicin PFS, Pharmorubicin RDF, Cisplatin, Platinol, Platinol-AQ, Capecitabine, Xeloda
Amgen
Gastric Cancer
11/14
08/15
CRITICS, NCT00407186 / 2006-004130-32: Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer

Active, not recruiting
3
788
Europe
cisplatin+capecitabine, radiotherapy, epirubicin+cisplatin+capecitabine
Dutch Colorectal Cancer Group, The Netherlands Cancer Institute, Roche Pharma AG
Gastric Cancer
12/18
12/25

Download Options